MOLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Molecular Partners AG (MOLN) is not a strong buy at this moment for a beginner investor with a long-term focus. The stock lacks clear positive catalysts, has weak financial performance, and no significant trading signals or recent news to support immediate investment. It is better to monitor the stock for further developments.
The technical indicators show a neutral to slightly bearish trend. The MACD is below 0 and negatively contracting, the RSI is at 31.944 (neutral), and the stock is trading near its support level of 4.162. Moving averages are converging, indicating no clear trend.
Analysts have a Buy rating with a $13 price target, citing the company's focus on addressing unmet oncology needs through its DARPin platform.
No recent news, weak financial performance with negative net income and EPS, and no significant insider or hedge fund trading activity. Technical indicators do not suggest a strong upward trend.
In Q4 2025, revenue remained at 0 with no growth. Net income improved slightly YoY but remains negative at -$12.65M. EPS also improved but is still negative at -0.34. Gross margin dropped to 0, showing no profitability.
H.C. Wainwright initiated coverage with a Buy rating and a $13 price target, highlighting the company's innovative oncology-focused platform. However, no other recent analyst updates are available.
